Literature DB >> 1682644

Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone.

J E Norman1, K J Thong, D T Baird.   

Abstract

A combination of the antiprogestagen mifepristone and an exogenous prostaglandin given by intramuscular injection or intravaginal pessary is a highly effective means of inducing abortion in early pregnancy. However, the search for a stable oral prostaglandin preparation has been largely unsuccessful. The effect of misoprostol, an orally active prostaglandin used to treat peptic ulcer, on uterine contractility was investigated in 33 women in early pregnancy (under 56 days' amenorrhoea). After administration of misoprostol in doses ranging from 200 micrograms to 600 micrograms, there was a significant increase in uterine pressure. In a second group of women who were given 200-1000 micrograms misoprostol 48 h after the administration of 200 mg mifepristone, there was a significant increase in the amplitude and frequency of uterine contractions. Complete abortion took place in 18 of the 21 women who received misoprostol after mifepristone, but in only 2 of 40 women given misoprostol alone. Our findings show that misoprostol increases uterine activity in early pregnancy and suggest that, in combination with mifepristone, it may be a highly effective method of inducing therapeutic abortion.

Entities:  

Keywords:  Abortion, Induced; Biology; Contraception; Contraceptive Usage; Developed Countries; Endocrine System; Europe; Evaluation; Family Planning; Fertility Control, Postconception; Genitalia; Genitalia, Female; Measurement; Method Acceptability; Northern Europe; Physiology; Pregnancy; Pregnancy, First Trimester; Prostaglandins--administraction and dosage; Reproduction; Research Methodology; Scotland; United Kingdom; Urogenital System; Uterine Effects; Uterus

Mesh:

Substances:

Year:  1991        PMID: 1682644     DOI: 10.1016/0140-6736(91)92102-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

Review 1.  Vaginal misoprostol for cervical ripening and induction of labour.

Authors:  G Justus Hofmeyr; A Metin Gülmezoglu; Cynthia Pileggi
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

2.  Medical abortion.

Authors:  K J Thong; D T Baird
Journal:  BMJ       Date:  1992-07-18

3.  Medical management of missed abortion and anembryonic pregnancy.

Authors:  H el-Refaey; K Hinshaw; R Henshaw; N Smith; A Templeton
Journal:  BMJ       Date:  1992-12-05

4.  Reproductive results associated with misoprostol and other substances utilized for interruption of pregnancy.

Authors:  Tatiane da Silva Dal Pizzol; Vera Lúcia Tierling; Lavinia Schüler-Faccin; Maria Teresa Vieira Sanseverino; Sotero Serrate Mengue
Journal:  Eur J Clin Pharmacol       Date:  2005-02-23       Impact factor: 2.953

5.  Misoprostol and attempted self-induction of abortion.

Authors:  M M Jones; K Fraser
Journal:  J R Soc Med       Date:  1998-04       Impact factor: 5.344

6.  Misoprostol as aid in First Trimester MTP.

Authors:  Shakti Vardhan; R C Behera; G S Sandhu; B K Goyal
Journal:  Med J Armed Forces India       Date:  2011-07-21

7.  Autism with ophthalmologic malformations: the plot thickens.

Authors:  Marilyn T Miller; Kerstin Strömland; Liana Ventura; Maria Johansson; Jose M Bandim; Christopher Gillberg
Journal:  Trans Am Ophthalmol Soc       Date:  2004

Review 8.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 9.  A benefit-risk assessment of misoprostol for cervical ripening and labour induction.

Authors:  Deborah A Wing
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 10.  Misoprostol to prevent and treat postpartum haemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects.

Authors:  G Justus Hofmeyr; A Metin Gülmezoglu; Natalia Novikova; Verena Linder; Sandra Ferreira; Gilda Piaggio
Journal:  Bull World Health Organ       Date:  2009-09       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.